BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28878089)

  • 1. HLA-B*14:02-Restricted Env-Specific CD8
    Leitman EM; Willberg CB; Tsai MH; Chen H; Buus S; Chen F; Riddell L; Haas D; Fellay J; Goedert JJ; Piechocka-Trocha A; Walker BD; Martin J; Deeks S; Wolinsky SM; Martinson J; Martin M; Qi Y; Sáez-Cirión A; Yang OO; Matthews PC; Carrington M; Goulder PJR
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28878089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoescape of HIV-1 in Env-EL9 CD8 + T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control.
    Moyano A; Blanch-Lombarte O; Tarancon-Diez L; Pedreño-Lopez N; Arenas M; Alvaro T; Casado C; Olivares I; Vera M; Rodriguez C; Del Romero J; López-Galíndez C; Ruiz-Mateos E; Prado JG; Pernas M
    Retrovirology; 2022 Mar; 19(1):6. PubMed ID: 35346235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential Immunodominance Hierarchy of CD8
    Adland E; Hill M; Lavandier N; Csala A; Edwards A; Chen F; Radkowski M; Kowalska JD; Paraskevis D; Hatzakis A; Valenzuela-Ponce H; Pfafferott K; Williams I; Pellegrino P; Borrow P; Mori M; Rockstroh J; Prado JG; Mothe B; Dalmau J; Martinez-Picado J; Tudor-Williams G; Frater J; Stryhn A; Buus S; Teran GR; Mallal S; John M; Buchbinder S; Kirk G; Martin J; Michael N; Fellay J; Deeks S; Walker B; Avila-Rios S; Cole D; Brander C; Carrington M; Goulder P
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29167337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells.
    Payne RP; Kløverpris H; Sacha JB; Brumme Z; Brumme C; Buus S; Sims S; Hickling S; Riddell L; Chen F; Luzzi G; Edwards A; Phillips R; Prado JG; Goulder PJ
    J Virol; 2010 Oct; 84(20):10543-57. PubMed ID: 20686036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.
    Wilson SE; Pedersen SL; Kunich JC; Wilkins VL; Mann DL; Mazzara GP; Tartaglia J; Celum CL; Sheppard HW
    AIDS Res Hum Retroviruses; 1998 Jul; 14(11):925-37. PubMed ID: 9686639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers.
    Ferre AL; Lemongello D; Hunt PW; Morris MM; Garcia JC; Pollard RB; Yee HF; Martin JN; Deeks SG; Shacklett BL
    J Virol; 2010 Oct; 84(19):10354-65. PubMed ID: 20668079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Env- and Gag-specific T cell responses in relation to programmed death-1 receptor and CD4 T cell loss rates in human immunodeficiency virus-1 infection.
    Pettersen FO; Taskén K; Kvale D
    Clin Exp Immunol; 2010 Aug; 161(2):315-23. PubMed ID: 20491784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted Gag-derived epitopes associated with relative HIV control.
    Berger CT; Frahm N; Price DA; Mothe B; Ghebremichael M; Hartman KL; Henry LM; Brenchley JM; Ruff LE; Venturi V; Pereyra F; Sidney J; Sette A; Douek DC; Walker BD; Kaufmann DE; Brander C
    J Virol; 2011 Sep; 85(18):9334-45. PubMed ID: 21752903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine.
    Schwerdtfeger M; Andersson AC; Neukirch L; Holst PJ
    J Transl Med; 2019 May; 17(1):175. PubMed ID: 31126293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential escape patterns within the dominant HLA-B*57:03-restricted HIV Gag epitope reflect distinct clade-specific functional constraints.
    Payne RP; Branch S; Kløverpris H; Matthews PC; Koofhethile CK; Strong T; Adland E; Leitman E; Frater J; Ndung'u T; Hunter E; Haubrich R; Mothe B; Edwards A; Riddell L; Chen F; Harrigan PR; Brumme ZL; Mallal S; John M; Jooste JP; Shapiro R; Deeks SG; Walker BD; Brander C; Landis C; Carlson JM; Prado JG; Goulder PJ
    J Virol; 2014 May; 88(9):4668-78. PubMed ID: 24501417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two Distinct Mechanisms Leading to Loss of Virological Control in the Rare Group of Antiretroviral Therapy-Naive, Transiently Aviremic Children Living with HIV.
    Vieira VA; Adland E; Grayson NE; Csala A; Richards F; Dacon C; Athavale R; Tsai MH; D'Souza R; Muenchhoff M; Bonsall D; Jooste P; Goulder PJR
    J Virol; 2022 Jan; 96(2):e0153521. PubMed ID: 34757843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-E-restricted HIV-1-specific CD8+ T cell responses in natural infection.
    Bansal A; Gehre MN; Qin K; Sterrett S; Ali A; Dang Y; Abraham S; Costanzo MC; Venegas LA; Tang J; Manjunath N; Brockman MA; Yang OO; Kan-Mitchell J; Goepfert PA
    J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34228645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-Cw*03-restricted CD8+ T-cell responses targeting the HIV-1 gag major homology region drive virus immune escape and fitness constraints compensated for by intracodon variation.
    Honeyborne I; Codoñer FM; Leslie A; Tudor-Williams G; Luzzi G; Ndung'u T; Walker BD; Goulder PJ; Prado JG
    J Virol; 2010 Nov; 84(21):11279-88. PubMed ID: 20739527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presence of HLA-C-restricted cytotoxic T-lymphocyte responses in long-term nonprogressors infected with human immunodeficiency virus.
    Nehete PN; Lewis DE; Tang DN; Pollack MS; Sastry KJ
    Viral Immunol; 1998; 11(3):119-29. PubMed ID: 9918403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of human immunodeficiency virus type 1 envelope as a T-cell immunogen.
    Peut V; Kent SJ
    J Virol; 2007 Dec; 81(23):13125-34. PubMed ID: 17898063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV Controllers Exhibit Enhanced Frequencies of Major Histocompatibility Complex Class II Tetramer
    Laher F; Ranasinghe S; Porichis F; Mewalal N; Pretorius K; Ismail N; Buus S; Stryhn A; Carrington M; Walker BD; Ndung'u T; Ndhlovu ZM
    J Virol; 2017 Apr; 91(7):. PubMed ID: 28077659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus.
    Khattar SK; Palaniyandi S; Samal S; LaBranche CC; Montefiori DC; Zhu X; Samal SK
    Hum Vaccin Immunother; 2015; 11(2):504-15. PubMed ID: 25695657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel immunodominant CD8+ T cell response restricted by a common HLA-C allele targets a conserved region of Gag HIV-1 clade CRF01_AE infected Thais.
    Buranapraditkun S; Hempel U; Pitakpolrat P; Allgaier RL; Thantivorasit P; Lorenzen SI; Sirivichayakul S; Hildebrand WH; Altfeld M; Brander C; Walker BD; Phanuphak P; Hansasuta P; Rowland-Jones SL; Allen TM; Ruxrungtham K
    PLoS One; 2011; 6(8):e23603. PubMed ID: 21887282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the human env-specific cytotoxic T-lymphocyte (CTL) response in natural human immunodeficiency virus type 1 infection: low prevalence of broadly cross-reactive env-specific CTL.
    Carmichael A; Jin X; Sissons P
    J Virol; 1996 Dec; 70(12):8468-76. PubMed ID: 8970969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-A*68:02-restricted Gag-specific cytotoxic T lymphocyte responses can drive selection pressure on HIV but are subdominant and ineffective.
    Kløverpris HN; Stryhn A; Harndahl M; Carlson JM; Leslie AJ; Chen F; Riddell L; Mulenga J; Walker BD; Ndung'u T; Buus S; Goulder P
    AIDS; 2013 Jul; 27(11):1717-23. PubMed ID: 23525031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.